English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The article discusses the institutional changes promoted by the federal government in order to facilitate an industrial policy for the pharmaceutical industry since 2003. The industrial policies like 2004's PITCE, PDP's 2008 and PBM's 2011, established the so-called economic-industrial complex health as a priority area of action. The government launched a series of measures to promote industrial development, such as subsidized credit supply, tax exemptions, incentives for universityindustry interaction, economic support, public investment, and especially the use of state purchasing power through demands of the SUS, to promote a policy of public-private partnerships to fund a technology transfer process for the local production of strategic medicines, such as antiretroviral drugs, oncological and biological products. Partnerships for Productive Development (PDPs) of the Ministry of Health, launched in 2008, represents the culmination of industrial policy geared to the pharmaceutical industry. Through a review of institutional changes, with emphasis on legislation, the aim of this article is to demonstrate the orchestration of interests and changes in the regulatory framework promoted by the federal government in order to apply a discretionary policy to build technological capabilities in national public and private laboratories, by using purchasing power of the state and including foreign laboratories in that process.

A POLÍTICA DE DESENVOLVIMENTO DA INDÚSTRIA FARMACÊUTICA BRASILEIRA DE 2003 A 2014